INTRODUCTION

SARS-CoV-2 is a new coronavirus with epicentre in the Hubei-region in China from where it spread globally in late 2019.\textsuperscript{1,3} As of 11 March 2020, WHO declared the situation a pandemic.\textsuperscript{4} Infection with SARS-CoV-2 leads to COVID-19, a disease ranging from mild respiratory illness to fatal pneumonia with acute respiratory distress syndrome (ARDS).\textsuperscript{2,5} SARS-CoV-2 has proven highly contagious and has put an immense strain on healthcare systems worldwide.
To avoid national health systems succumbing to the large patient load with the inevitable increments in patient mortality, WHO recommended a rapid case identification, testing and isolation strategy on 14 April 2020. This is to be followed by comprehensive contact tracing and quarantine of contacts. So far, this approach has been associated with lower hospitalization rates and fatality in countries enacting this strategy. Government responses have ranged from travel restrictions to essentially complete shutdown of numerous countries around the globe.

As social distancing is not a viable long-term stand-alone strategy, pharmacological treatment of infected patients is necessary until herd immunity is reached by widespread viral outbreaks or an effective prophylactic vaccine. As of November 2020, only corticosteroids have proven conclusively successful in the treatment of COVID-19 with dexamethasone reducing overall 28-day mortality in hospitalized patients with severe COVID-19. In patients with invasive mechanical ventilation, dexamethasone treatment reduced lethality from 41.1% in placebo group to 28.3% in the treatment group, whereas no effect was found when patients did not receive respiratory support at randomization. Initially, Remdesivir was found to shorten the duration of hospitalization but in a yet to be peer-reviewed study, the intravenous drug was found to be ineffective (n = 2750) alongside hydroxychloroquine (n = 954), Lopinavir (n = 1411) and interferon (n = 1412 and in combination with Lopinavir: n = 651) in a large international randomized study on more than 11 000 inpatients in 30 countries. On 22 October 2020, Remdesivir received full FDA approval as treatment of COVID-19 in hospitalized adults and paediatric patients (older than 12 years and weighing at least 40 kg) but with the inconsistent findings and intravenous delivery method, out-patient use of the drug is complicated and questionable. Moreover, a global backorder and high cost adds to the complexity of broad treatment with Remdesivir.

The viral replication cycle has been thoroughly studied for the closely related coronavirus SARS-CoV, the cause of the 2002-2003 severe acute respiratory syndrome (SARS) outbreak, and to a lesser degree for SARS-CoV-2. Here, new pharmacological targets have emerged. Of particular interest is the viral host cell entry mechanism. Blocking viral host cell entry will efficiently stop viral replication and disease progression. Camostat mesylate is a serine protease inhibitor that shows promise in cell cultures in combating SARS-CoV-2 through limiting viral entry. Camostat mesylate has been clinically used for treatment of pancreatitis and reflux oesophagitis for over two decades. The drug has few and mild side effects even at high dosages and is readily produced at low costs. Our goal is to review current knowledge on camostat mesylate and the pharmacological actions that may prove fruitful in combating SARS-CoV-2 and the COVID-19 pandemic.

SARS-CoV-2 is an enveloped positive-strand RNA virus (+ssRNA virus) that transmits from person-to-person through respiratory droplets and by direct contact. The initial infection is presumed to occur in the mucosal epithelium in the upper respiratory tract. In milder cases, the infection is controlled by the immune system at this point, but a further involvement of the lung is often observed. The helical nucleocapsid is surrounded by a viral envelope that holds a two-subunit spike protein. The outer S1-subunit of the spike enables receptor binding whereas the S2 subunit enables membrane fusion (Figure 1). Upon interaction between the mucosal epithelial cell and virus, the S1 subunit binds to the host cell angiotensin-converting enzyme 2 (ACE2) receptor. The specificity to the ACE2-receptor and the host proteases leads the virus to primarily replicate in the epithelium of the lung and respiratory tract where ACE2 protein expression is high especially in the lower respiratory tract. As SARS-CoV-2 closely resembles SARS-CoV, it has been hypothesized that many of the SARS-CoV viral cell entry mechanisms also apply to SARS-CoV-2.

Upon ACE2 binding, the SARS-CoV-2 spike proteins are proteolytically processed at the S1/S2- and S2 sites by host proteases. The proteases at the cell surface include furin, the cell surface proteases TMPRSS2 and to a minor degree TMPRSS13, TMPRSS11D, −11E and 11F. The lysoosomal proteases include cathepsin L/B (Figure 1). Consequently, this pathway is only active to a minor extent. Internal fusion machinery in the spike protein is activated and mediates fusion of cell/vesicle membrane and virus envelope, thus the nucleocapsid is released to the host cell cytoplasm where the virus starts replicating. During infection, the virus may trigger release of pro-inflammatory cytokines including IL-8, IL-6 and TNF-α leading to tissue damage with subsequent vascular leakage. If left uncontrolled, this disease process can give rise to a cytokine release storm with lymphocyte infiltration. This picture, similar to macrophage activation syndrome (MAS), can thus lead to lung tissue damage and oedema eventually resulting in life-threatening respiratory failure. Furthermore, the virus may be able to downregulate and shed ACE2 leading to dysfunction of the pulmonary renin-angiotensin-system, causing vascular permeability and further complicating the inflammatory state.

CAMOSTAT MESYLATE INHIBITS SARS-COV-2 HOST CELL ENTRY

As viral load may be associated with negative outcome, restricting viral cell entry and thereby reducing of overall viral
load could slow disease progression. This, in turn, increases the timespan in which the innate and adaptive immune system can combat the virus resulting in reduced cytokine-mediated tissue damage. Reducing viral and host cell membrane fusion is more efficient for viral entry reduction than endosomal pathway inhibition.\(^{12,26,30}\)

A candidate drug to reduce viral host cell entry is camostat mesylate. Camostat mesylate is attractive as an antiviral agent, as it inhibits many of the serine proteases that SARS-CoV and SARS-CoV-2 use for virus-to-host cell membrane fusion, like TMPRSS2, −13, and −11D/E/F (Figure 1).\(^{26,31,32}\) The lack of extracellular proteases like TMPRSS2 reduces cellular infection rate of SARS-CoV more than 100-fold\(^{13}\) making these proteases a convincing target when combating SARS-CoV-2 infection. Using camostat mesylate to block virus-membrane fusion may diminish viral infection by two thirds\(^{32}\) and hence reduce the likelihood of severe infection and the accompanying morbidity and mortality. The knock-on effect of reducing patient days of hospitalization could ease the burden on healthcare systems and enable reduction in stringency of government restrictions.

A preclinical animal study showed that when mice are given a fatal dose of SARS-CoV, lethality can be reduced by 60% with twice daily administration of 30 mg/kg camostat mesylate.\(^{30}\) In vitro studies of SARS-CoV-2 in a human lung cell line and primary human lung epithelial cells have revealed significant reduction in SARS-CoV-2 spike protein driven cellular entry.\(^{12}\) Cell entry in a human colon epithelium cell line by SARS-CoV-2 spike protein expressed pseudotyped-virus is partially blocked by camostat mesylate. In a primate kidney epithelium cell line, camostat mesylate is efficient in blocking spike protein-induced fusion only when TMPRSS2 is present,\(^{12}\) emphasizing the importance of this specific protease for the action of camostat mesylate.

**FIGURE 1** Illustration of SARS-CoV-2 entry mechanisms. Viral host cell entry through airway epithelium is initiated by the receptor-binding domain (RBD) of the viral spike protein binding to host cell angiotensin-converting enzyme 2 (ACE2). Upon ACE2 binding, the spike proteins are proteolytically processed by host proteases in either lysosomal vesicles after endocytosis or at the cell surface. The cell surface entry mechanism has proven the most efficient and is mediated by Transmembrane Serine Proteases (TMPRSS). These can be blocked by serine protease inhibitors like camostat mesylate efficiently reducing host cell viral uptake.
4 | CAMOSTAT MESYLATE MODE OF ACTION

Camostat mesylate is a potent inhibitor of TMPRSS2, −13, and 11D/E/F.26 TMPRSS2 is a type II transmembrane serine protease that is widely expressed in epithelial cells but with a yet unknown physiological function. The protease has been shown to facilitate cell entry of numerous viruses including influenza, SARS and MERS.12,30,31,34,35 Whereas furin cleaves the spike protein at the S1/S2 site, TMPRSS2 cleaves it at the 2′ site, which has been proposed to activate the membrane fusion activity of the spike protein.25,36 Multiple TMPRSS2 inhibitors have been proven efficient in combating SARS-CoV-2 infection in vitro confirming TMPRSS2 as being a key mediator of viral entry.25

Upon human oral dosing, camostat mesylate is a pro-drug which has a short plasma half-life of <1 minute.13,37 Hydrolysis of the dimethyl acetamide side-chain ester group in ex vivo plasma preparations and in vivo, in the gut or readily after systemic uptake, produces GBPA (4-(4-guanidino-benzoyl-oxyl)phenylacetic acid)37 also known as FOY-251. GBPA is equally potent inhibitor of TMPRSS2 and distributes to well-perfused organs including the lungs.26,37 The half-life of GBPA after intravenous infusion of the parent drug is roughly an hour before being metabolized to GBA which is not a TMPRSS2 inhibitor.37

Based on the accepted inhibition of the enzymatic catalytic mechanism and the available X-ray crystal structure derived picture of camostat mesylate soaked in Prostasin (PDB 3FVF) (Figure 2), also a serine protease, it is known that camostat mesylate or GBPA bind in the protease active site.38 Here, camostat mesylate or GBPA is cleaved by the triad His85-Asp134-Ser238 (corresponding to His296-Asp345-Ser441 in human TMPRSS2), forming a covalent bond between the carboxy warhead of GBA and serine 238.38 It is not known whether the observed covalent bond (in 3FVF) results similarly in an irreversible inhibition of TMPRSS2, which then should be taken into account when determining dosing and timing in relation to TMPRSS2 turnover. In silico, modelling of the TMPRSS2-targeting camostat mesylate and bromhexine in the TMPRSS2 model structure predicts that the complete or “intact” camostat mesylate structure fits across the three, proposed, sub-pockets, namely the S1 (oxyanion hole), the catalytic triad domain and the hydrophobic patch.39 Furthermore, the models predict efficient hydrogen bonding and Van-der-Walls interactions of camostat mesylate across the three domains (eg Asp435 at S1, catalytic Ser441 and His296 at the distal hydrophobic patch). By comparison, bromhexine is predicted to bind at the hydrophobic patch domain only.40,41 Thus, rationalizing the in vitro inhibition constant (Ki) of 1.51 µM compared with 43.00 µM (camostat mesylate vs bromhexine). Camostat mesylate is therefore the theoretically more potent binder of the two drugs in terms of SARS-CoV-2 host virus-membrane fusion inhibition. However, by analogy to recently42 and previously reported studies, camostat mesylate and its active metabolite GBPA are expected to be, not only competitive inhibitors of TMPRSS2, but also substrates leading to covalent inhibition.38,42 Further experimental work is necessary to establish the exact nature and molecular mechanism of inhibition of TMPRSS2 by camostat mesylate and GBPA, establishing the relevance of its pseudo irreversible inhibition38 for human PK-PD modelling. In vivo plasma profile of GBPA, the metabolic substrate of camostat mesylate, may be the more relevant species binding to the enzyme. Studies are, equally, needed to understand, in silico, the GBPA binding mode, as a critical step to design superior in vivo analogues of GBPA. The understanding of the human whole-body pharmacokinetics and—dynamics may prove more important than binding affinity and—strength in the target organ.

5 | CAMOSTAT MESYLATE AS A TREATMENT OPTION DURING INFECTION

Based on the current knowledge of SARS-CoV-2 spike protein-mediated host membrane fusion, the use of camostat mesylate as a prophylactic or early phase COVID-19 treatment option is compelling. However, as influenza virus also use serine proteases such as TMPRSS2 for host cell entry, some additional knowledge can be gained from studies on camostat mesylate in influenza virus infection in human epithelial cell cultures. These indicate a reduction in viral replication even if treatment is initiated after host cell infection.35 Furthermore, camostat mesylate reduced the inflammatory markers IL-6 (7-fold) and TNF-α (3-fold) in the cell supernatants compared with non-treated controls five days post-infection. As COVID-19 disease progresses, the viral titre may not correlate with the severity of disease.43,44 This indicates that immunopathological processes may worsen the condition and, in some cases, cause a potentially fatal cytokine storm. For SARS-CoV infection, and possibly also for SARS-CoV-2, further lung damage and worsening of the disease can be seen even at low viral loads. Indeed, antiviral treatment should preferably be started as soon as possible before the inflammatory cytokine storm is accompanied by immunopathogenic changes and the damage becomes too extensive.29 However, there may still be a reason for camostat mesylate treatment initiation after onset of severe COVID-19. SARS-CoV spikes are potent stimulators of the pro-inflammatory cytokine transforming growth factor-beta (TGF-β).45,46 As seen during other uncontrolled cytokine storms, TGF-β has been shown to play an important part in progressive fibrosis in COVID-19-mediated ARDS.47 TGF-β has therefore been proposed as a relevant pharmacological
target in the pandemic. Studies in laboratory animals have revealed that camostat mesylate reduces TGF-β and accompanied fibrosis increasing the likelihood of camostat mesylate to alleviate COVID-19-induced ARDS.

6 CAMOSTAT MESYLATE SAFETY

Camostat mesylate has been thoroughly tested and used as a human therapeutic for more than two decades (Table 1). It is primarily used for symptomatic relief for conditions in the upper gastrointestinal tract. When used in the treatment of acute worsening of chronic pancreatitis or postoperative reflux oesophagitis, the recommended dosage is 300-600 mg/day in three dosages of 100-200 mg. The side effects are usually mild and include rash and pruritus (<0.5%), nausea or abdominal discomfort (<0.5%) and liver enzyme elevation (<0.5%). Common for the side effects is that they cease when drug administration is discontinued. This may be true even for much higher dosages, as no significant side effects were seen in 9 patients treated with 7.2 g/day for up to 8 months. With adverse effects generally being mild even at very high dosages for prolonged periods of time, the most important aspect, if camostat mesylate is to be used in combating COVID-19, is to reach the plasma concentration sufficient to inhibit viral replication.

7 CAMOSTAT MESYLATE DOSING IN COVID-19

Camostat mesylate reduces SARS-CoV-2 cell entry in cell cultures by 50% (EC90) at a concentration of 1 µM and 90% at 5 µM (EC90). If in vitro data are translatable, the concentration in the lungs needs to surpass 1 µM to achieve 50% effective concentration. However, in vitro studies in Influenza A/H1N1 (responsible for the 2009 pandemic) and A/H3N2 infection models revealed a concentration-dependent decrease in viral supernatant titres at concentrations even lower than this. A significant reduction was found at concentrations as low as 0.01 µg/mL equivalent to 0.02 µM (Table 1). Pharmacokinetic studies revealed substantial distribution of camostat mesylate/GBPA to the lungs in both rats and dogs 10 minutes after a single intravenous bolus of camostat mesylate. There was a tendency for the drug to concentrate in tissue and to eliminate at a slower rate than in plasma indicating tissue binding or uptake. When reducing mortality by 60% after viral challenge with SARS-CoV in mice, camostat mesylate was dosed at 30 mg/kg twice daily. Unfortunately,
plasma concentrations of camostat mesylate and metabolites were not determined in the mice. This dose (30 mg/kg) is equivalent to 2100 mg × 2 in a 70 kg human when translating dose per weight. If dose is translated on the basis of body surface area, which may be more relevant when comparing man and mice, the dose would be 170 mg × 2 daily in a 70-kg human.50 Mice are known to metabolize substrates at a higher rate than humans,51 thus a lower dose could be equally efficient in humans. Healthy fasting humans given a single oral dose of 100 mg camostat mesylate reach maximal plasma levels of GBPA 0.15 µM (unpublished data). It is therefore likely that camostat mesylate doses well below 2100 mg will be sufficient in achieving relevant SARS-CoV-2 inhibitory plasma concentrations.

| Species | Study group | Dosage | Study |
|---------|-------------|--------|-------|
| Human   | Healthy Caucasian males | 40 mg in 120 mL saline infused iv over 12 hours | Midgley, I et al37 |
| Human   | Case Report: A 69-year-old woman with Evans syndrome | 500 mg/day | Nakao, A et al59 |
| Human   | Case Report: Two patients with ulcerative colitis | 600 mg/day | Senda, S et al60 |
| Human   | Suspected pancreatic disease | 200 mg × 3/day for 2 weeks | Sai, JK et al61 |
| Human   | Three patients with diabetic nephropathy with the nephrotic syndrome | 600 mg/day | Ikeda, Y et al62 |
| Human   | Diabetic nephropathy | 600 mg/day for 4 weeks (Camostat mesylate) | Onbe, T et al63 |
| Human   | Fourteen patients, age 4-16 years, with an abnormal urinalysis | 100 mg × 2/day | Asami, T et al66 |
| Human   | Fifteen patients with a mild grade of chronic pancreatitis | 200 mg × 3/day | Sugiyama, M et al67 |
| Human   | Patients Gastro-oesophageal reflux disease | 300 mg × 3/day for 4 weeks | Kono, K et al68 |
| Human   | Nine patients, age 41-63 years, with squamous cell carcinoma | Up to 7.2 g/day | Okkoshi, M et al69 |
| Human   | 12 healthy volunteers | 500 mg × 4/day for 4 weeks | Friess, H et al70 |
| Human   | 24 patients, age (mean ± SD) 59 ± 14 years, with unexplained dyspepsia | 200 mg × 3/day for 4 weeks | Ashizawa, N et al71 |
| Human (cells) | Calu-3-cells and H3255 cells infected with 293FT cells expressing SARS-2-S proteins | 10-100 nM | Yamamoto, M et al72 |
| Human (cells) | Calu-3-cells infected with pseudotype particles bearing SARS-2-S proteins | 0.01-100 µM | Hoffmann, M et al73 |
| Human (cells) | Calu-3-cells infected with SARS-CoV-2. Primary human airway epithelial cells infected with pseudotype particles bearing SARS-2-S proteins | Calu-3 cells: 1-500 µM Primary cells: 10 µM and 50 µM | Hoffmann, M; Kleine-Weber, H et al74 |
| Human (cells) | Calu-3-cells infected with SARS-CoV-2 or SARS-2-S bearing VSV particles | SARS-CoV-2 entry: 100 nM or 100 µM. SARS-2-S bearing entry: 1-100 µM. | Hoffmann, M; Schroeder, S et al75 |
| Human (cells) | Calu-3-cells infected with SARS-CoV | 10 µM | Kawase, M et al76 |
| Human (cells) | Calu-3-cells infected with 293FT cells expressing MERS-S proteins | 0.01, 0.1, 1 or 10 µM | Yamamoto, M; Matsuyama, S et al77 |
| Human (cells) | Calu-3-cells (and other lung-derived cell lines) infected with MERS-CoV | 1, 10 and 100 µM | Shirato, K et al78 |
| Human (cells) | human tracheal epithelial cells infected with A/H1N1 or A/H3N2 | 10 µg/mL | Yamaya, M et al79 |
| Mice | Mice infected with SARS-CoV | 30 mg/kg × 2/day for 9 days | Zhou, Y et al80 |
| Mice | Mice infected with A/H1N1 | 1.95 mg/mL/100 g BW, IP × 2/day for 7 days | Lee, M. G. et al81 |
The COVID-19 pandemic has accentuated the need for drug repurposing while awaiting the pharmaceutical development of highly potent antiviral compounds against SARS-CoV-2. So far, anti-inflammatory corticosteroids are the only available option for the vast majority of patients and healthcare professionals burdened by the pandemic, as Remdesivir accessibility is restricted. Until a specific anti-SARS-CoV-2 drug is developed, the use of compounds with favourable safety profiles is essential when attempting to reduce morbidity and mortality. SARS-CoV-2 virions stimulate the respiratory epithelium and immune cells to produce cytokines and chemokines which cause leukocyte infiltration and potential lung damage, lung oedema, and in the most severe cases compromised gas exchange.52 Camostat mesylate has been tested on numerous patient groups with large age spans and therefore appropriately covers the diverse demography of patients suffering from COVID-19. Moreover, safety data on small groups of patients, cover a large span of doses achieving the antiviral concentrations found in human cells and mice (Table 1). A possible advantage of blocking a critical host component like TMPRSS2 using camostat mesylate, and not targeting the virus itself, is that it will be more resilient to the rapid development of viral resistance, since individual point mutations in viral components are unlikely to compensate for the loss of a critical host factor.53 On the other hand, one of the drawbacks of a drug limiting cell entry may be the need for early treatment initiation during the first phase of the infection to minimize cell damage and cytokine production,18 hence treatment may have to be initiated before occurrence of severe COVID-19.54,56 The majority of antiviral studies have been done on mice and human cells pretreated with camostat mesylate.12,30,35,57 However, in these studies, the viral challenge dose administered presumably far surpasses the loss of a critical host factor.53 On the other hand, one of the drawbacks of a drug limiting cell entry may be the need for early treatment initiation during the first phase of the infection to minimize cell damage and cytokine production,18 hence treatment may have to be initiated before occurrence of severe COVID-19.54,56

In conclusion, based on human cell and animal studies, camostat mesylate is a promising repurposed drug against COVID-19 by inhibiting viral particle entry and possibly inflammation, and the drug has an excellent safety profile in humans. The results of the ongoing trials worldwide will be awaited with interest, and further trials will be necessary for investigating synergy with other anti-SARS-CoV-2 drugs.

ACKNOWLEDGEMENT
We thank the Lundbeck Foundation for financing CamoCO-19 (NCT04321096), and supporting this review (OSS, MK).

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

ORCID
Jesper Damsgaard Gunst https://orcid.org/0000-0002-3787-0259
Mads Kjolby https://orcid.org/0000-0002-1043-6137

REFERENCES
1. Khan S, Siddique R, Shereen MA. et al. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. Journal of Clinical Microbiology. 2020;58 (5):106006.
2. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. 2020;20(2):124-127.
3. Deslandes A, Berti V, Tandjaoui-Lambotte Y, et al. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020;55(6):531-532.
4. WHO. Virtual press conference on COVID-19 – 11 March 2020. Secondary Virtual press conference on COVID-19 – 11 March 2020 11 March 2020. https://www.who.int/docs/default-source/coronaviruse TRANSCRIPTS/WHO-AUDIO-EMERGENCIES-Coronavirus-PRESS-CONFERENCE-FULL-AND-FINAL-11MAR2020.pdf?sfvrsn=cb432b63_2
5. Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respiratory Med. 2020;8(8):S816-821.
6. Horby P, Lim WS, Emberson, Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020. http://dx.doi.org/10.1056/NEJMoa2021436.
27. Beigel JH, Tomaszek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine. 2020;383 (19):1813–1826. http://dx.doi.org/10.1056/nejmoa2007764.

22. Hamming I, Timens W, Bulthuis M, Lely A, Gv N, van Goor H. Adaptation of the human pancreas to inhibition of luminal proteolytic activity. Gastroenterology. 1998;115(2):388-396.

10. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 2020;63(3):457-460.

8. Pan H, Petrò R, Karim QA, et al. Repurposed antiviral drugs for COVID-19: interim WHO SOLIDARITY trial results. medRxiv 2020.

7. Beigel JH, Tomaszek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine. 2020;383 (19):1813–1826. http://dx.doi.org/10.1056/nejmoa2007764.

6. Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv 2020.

5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-292.e6.

4. Pan H, Petrò R, Karim QA, et al. Repurposed antiviral drugs for COVID-19: interim WHO SOLIDARITY trial results. medRxiv 2020.

3. Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv 2020.

2. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-292.e6.

1. Li F. Structure, function, and evolution of coronavirus spike proteins. Nature. 2009;115(2):388-396.
benefits. Journal of Pharmacology and Experimental Therapeutics. 2020;JPET–AR. http://dx.doi.org/10.1124/jpet.120.000219.

43. Petris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767-1772.

44. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20(6):697-706.

45. He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210(3):288-297.

46. Zhao X, Nicholls JM, Chen Y-G. Severe Acute Respiratory Syndrome-associated Coronavirus Nucleocapsid Protein Interacts with Smad3 and Modulates Transforming Growth Factor-β Signaling. Journal of Biological Chemistry. 2008;283 (6):3272-3280. http://dx.doi.org/10.1074/jbc.m70833200.

47. Ferreira-Gomes M, Kruglov A, Durek P, et al. In severe COVID-19, SARS-CoV-2 induces a chronic, TGF-β-dominated adaptive immune response. medRxiv 2020.

48. Chen W. A potential treatment of COVID-19 with TGF-β blockade. Int J Biol Sci. 2020;16(11):1954.

49. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-β. Gastroenterology. 2001;120(7):1784-1800.

50. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal models to humans for pharmacokinetic and pharmacodynamic studies. Journal of Pharmacology and Experimental Therapeutics. 2008;283 (6):3272–3280.

51. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875-894.

52. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38(4):471-482.

53. Prussia A, Thepchatri P, Snyder JP, Plemper RK. Systematic approaches towards the development of host-directed antiviral therapeutics. Int J Mol Sci. 2011;12(6):4027-4052.

54. Liu Y, Liao W, Lan L, Xiang T, Zhang W. Correlation Between Clinical and Biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 2020;63(3):364-374.

55. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. J. Investig. Med. 2020;68(11):1260-1267.

56. Yu F, Yan L, Wang N, et al. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin Infect Dis. 2020;71(15):793-798.

57. Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S. Nafamostat Mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64:e00754-20.

58. Hofmann-Winkler H, Moer O, Alt-Epping S, et al. Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. Critical Care Explorations. 2020;2(11):e0284http://dx.doi.org/10.1097/cecc.0000000000000284.

59. Nakao A, Iwagaki H, Notohara K, et al. Successful resection of rectal carcinoma in an Evans’ syndrome patient followed by prednisolone and high-dose immunoglobulin: report of a case. Acta Med Okayama. 2001;55(4):253-257.

60. Senda S, Fujiyama Y, Bamba T, Hosoda S. Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med. 1993;32(4):350-354.

61. Sai JK, Suyama M, Kubokawa Y, Matsumura Y, Inami K, Watanabe S. Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. J Gastroenterol. 2010;45(3):335-341.

62. Ikeda Y, Ito H, Hashimoto K. Effect of camostat mesilate on urinary protein excretion in three patients with advanced diabetic nephropathy. J Diabetes Comp. 1999;13(1):56-58.

63. Onbe T, Makino H, Kumagai I, Haramoto T, Murakami K, Ota Z. Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy. J. Diaboly. 1991;5(2-3):167-168.

64. Matsubara M, Taguma Y, Saito T, Yoshinaga K. Anti-proteinuric and anti-coagulatory effects of camostat mesilate in azotemic diabetics. Nihon Jinzo Gakkai Shi. 1991;34(4):411-416.

65. Matsubara M, Taguma Y, Kurosawa K, Hotta O, Suzuki K, Futaki G. Effect of camostat mesilate on heavy proteinuria in various nephropathies. Clin Nephrol. 1989;32(3):119-123.

66. Asami T, Tomisawa S, Uchiyama M. Effect of oral camostat mesilate on hematuria and/or proteinuria in children. Pediatric Nephrol. 2004;19(3):313-316.

67. Sugiyama M, Ato O, Wada N, Kuroda A, Muto T. Effect of oral protease inhibitor administration on gallbladder motility in patients with mild chronic pancreatitis. J Gastroenterol. 1997;32(3):374-379.

68. Kono K, Takahashi A, Sugai H, et al. Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity. Am J Surg. 2005;190(3):412-417.

69. Ashizawa N, Hashimoto T, Miyake T, Shizuku T, Imaoka T, Kinoshita Y. Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: Is camostat mesilate effective? J Gastroenterol Hepatol. 2006;21(4):767-771.

70. Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant and anti-fibrinolytic effects of camostat mesilate against SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses. 2020;12(6):629.

71. Yamamoto M, Matsuoka S, Li X, et al. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60(11):6532-6539.

How to cite this article: Breining P, Frölund AL, Højen JF, et al. Camostat mesylate against SARS-CoV-2 and COVID-19—Rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2021;128:204–212. https://doi.org/10.1111/bcpt.13533